Objective: To evaluate the clinical value of senescence marker protein 30 (SMP30) and anti-SMP30 antibody in serum.
hepatocellular carcinoma (HCC) histological subtype is highly common in China; this subtype ranks first among all malignant tumors in Guangxi province. Despite the improvement in diagnosing and treatment of HCC, 5-year overall survival for the patients is only 3% to 5%. 3 This finding is partly attributed to the lack of a reliable method for early diagnosis (to our knowledge). So far, alpha-fetoprotein (AFP) has been used as the most common serum biomarker for diagnosis of HCC. However, its sensitivity is only 25% to 65% at the standard cutoff of 25 ng per mL, especially when diagnosing in the early stages of HCC. 4 Therefore, it is important to develop serological markers for effectively diagnosing HCC at early stages and to monitor aggressiveness, responsiveness to treatments, tumor recurrence, and patient survival rate.
It has been shown that senescence marker protein 30 (SMP30), otherwise known as regucalcin (RGN), a calcium-binding protein discovered by Fujita et al in 1992, 5 plays a crucial role in protective effects against apoptosis and oxidative stress. 6 Using the serologic identification by (cDNA) expression library as being an HCC-associated antigen. 7 The results of immunohistochemical analysis showed that the levels of SMP30 expression in HCC paracancerous tissues were higher than those in the corresponding HCC. 8 The low expression of SMP30 protein in HCC is closely related to the survival prognosis for patients. 9 The aforementioned studies have shown that expressions of SMP30 are important in the progression of liver cancer. However, whether the concentration of SMP30 in serum can be used as a diagnostic indicator of liver cancer has not been reported, to our knowledge.
Numerous studies 10, 11 have shown that the tumor itself can induce the immune response of the body to produce antibody related to the antitumor antigen. This response can be tested even when the tumor antigen expression is low. Therefore, the antibody related to the antitumor antigen is understood as the symbol of tumor diagnosis. 12 Previously, Western blotting (WB) has been used to confirm the presence of SMP30 and anti-SMP30 antibody in the serum of patients with HCC, which suggests that detection of SMP30 and anti-SMP30 antibody levels may be understood as auxiliary indices for HCC diagnosis. 13 However, as a serological diagnostic index of HCC, the specificity and sensitivity of those methods for HCC diagnosis still requires greater nontumor serological verification. Based on the aforementiond analyses, we have examined the levels of serum SMP30 together with anti-SMP30 antibody in 495 serum specimens from 143 patients with HCC, 51 patients with liver cirrhosis (LC), 137 patients with chronic hepatitis (CH), and 165 healthy control individuals to validate the diagnostic value.
Materials and Methods

Patients and Specimen Obtaining Procedures
The BL21 (DE3) pLysS-pColdIII-SMP30-pTf16 recombinant genetic-engineering strain was constructed by our research team and stored at −80°C. 14 This study included 331 patients, of whom 143 with HCC were recruited by the Affiliated Tumor Hospital of Guangxi Medical University, China. A total of 137 patients with CH and 51 with LC were followed up at the first Affiliated Hospital of the same university. The diagnoses of CH and LC were carried out by abdominal ultrasound scanning and laboratory testing.
Patients with HCC were diagnosed by histology and laboratory testing, including computed tomography (CT) scanning, abdominal ultrasound scanning, and magnetic resonance imaging (MRI). The clinical stages were classified according to the International Union against Cancer TNM classification. 15 Neither chemotherapy nor surgical treatments had been given to the patients. Physical examinations and laboratory tests were performed at the time that blood specimens were obtained. The normal human serum (NHS) specimens were obtained from 165 healthy college students, aged 17 through 23, who had tested negative for hepatitis B surface antigen (HBsAg) and whose liver function and abdominal ultrasound test results revealed no abnormalities ( Table 1 ). The investigation procedures were conducted in compliance with the guidelines of the Ethical Committee of Guangxi Medical University. Oral informed consent was obtained from all participating patients and healthy donors. The serum specimens were divided into aliquots and stored at −80°C until they were analyzed.
Preparation of Soluble Recombinant HIS-SMP30 Protein
We prepared soluble recombinant HIS-SMP30 protein in our laboratory. In brief, the BL21(DE3)pLysS-pColdIII-SMP30-pTf16 recombinant genetic-engineering strain was cultured and induced by isopropyl β-D-1-thiogalactopyranoside (IPTG) to express HIS-SMP30; the fusion protein is 165 amino acids near the C-terminal. The supernatant of bacteria with sonication was harvested and loaded into the nitrilotriacetic acid (Ni-NTA) affinity column, and then purified HIS-SMP30 genetic-engineering protein was obtained.
We performed verification testing of the target protein by WB in which the primary antibody was the murine-origin anti-SMP30 monoclonal antibody and the secondary antibody was goat anti-mouse horseradish peroxidase-conjugated immunoglobulin G (IgG-HRP). The aliquots of target protein were frozen and stored at −80°C for further use.
Indirect Enzyme-Linked Immunosorbent Assay (ELISA) for Serum Anti-SMP30 Antibody
We used 2.5 μg per mL purified HIS-SMP30 protein to coat the ELISA plate at 4°C overnight. The wells were then emptied and washed 3 times with phosphate-buffered saline with Tween 20 (PBST) and with 0.5% bovine serum albumin (BSA) closure at 37°C for 1 hour. We then added serum diluted (1:1024) with PBST at 37°C for 1 hour; all serum specimens underwent this process twice. After washing, we added biotin goat anti-human IgG antibody (Boster Biological Engineering) to the wells and then incubated the resulting product for 1 hour at 37°C, followed by washing. The horseradish peroxidase (HRP)-avidin was added for 40 minutes at 37°C, the plates were washed, and 100 μL of tetramethyl benzidine (TMB) substrate solution was added. The TMB color development was conducted for 15 minutes and then 2 M of sulfuric acid was used to terminate the reaction. The optical densities were read at 450 nm using a microplate reader. The optical density (OD) values of all the results were deducted from the blank control values, and the result was determined by the X +3SD of the NHS group as the cutoff value.
Double Antibody Sandwich ELISA for Serum SMP30
ELISA plates were prepared by coating them with 100 μL per well of rabbit anti-human SMP30 polyclonal antibody at 4°C overnight. The wells were emptied, followed by washing 3 times with PBST, and with 0.5% BSA closure at 37°C for 1 hour. All serum specimens were diluted to 1:5 with PBST and loaded with 100 μL of diluted serum per well. The plates were incubated for 1 hour at 37°C and washed 3 times. The plates were incubated with 100 μL per well of mouse anti-human SMP30 monoclonal antibody for 1 hour at 37°C. The plates were once again washed 3 times and then incubated with 100 μL per well of goat anti-mouse IG-HRP solution in phosphate-buffered saline (PBS).
After all the aformentioned treatments, the plates were further incubated for 1 more hour at 37°C plus washing. We then added 100 μL of TMB substrate solution. The TMB color development was conducted for 15 minutes, and then 2 M of sulfuric acid was used to terminate the reaction. We used a microplate reader to read the OD values at 450 nm.
The OD values of all the results were deducted from the blank control results, and the result was determined by the X +3SD of the NHS group as the cutoff value.
Statistical Analysis
We adapted SPSS statistical software, version 17.0 (IBM) and GraphPad Prism software (GraphPad Software, Inc) for analyses. We conducted receiver operating characteristic (ROC) analyses to assess sensitivity, specificity, and area under the curve (AUC) with 95% confidence intervals 
Results
Expression and Identification of the Interest Protein
We used sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) electrophoresis on the identified genetic-engineering protein HIS-SMP30. The results ( Figure 1A) showed that the target product could be well separated and purified under NTA-100 conditions. A protein fragment of approximately 21 kDa can appear in the purified product; this finding is consistent with the previous results. 14 To verify whether the expressed protein is the protein of interest, anti-SMP30 antibody has been used simultaneously in carrying out WB experiments. The results of WB have shown that the purified protein can be combined with anti-SMP30 antibody ( Figure 1B) . The HIS-SMP30 antigenic protein fragment that can be combined with the anti-SMP30 antibody has been expressed efficiently.
The results of WB confirmed that the extracted protein and the protein were effectively bound with anti-SMP30 antibody. SMP30 protein meets the experimental requirements of ELISA and can be used to detect the presence of antibody in serum.
Positive Rates of SMP30 and Anti-SMP30 Antibody in Serum Specimens
ELISA has been used to detect the absorbance of SMP30 and anti-SMP30 antibody in the serum of patients with HCC, CH, and LC, as well as the healthy control group. According to X +3SD of absorbance in the healthy control group, the cutoff values of SMP30 and anti-SMP30 antibody in serum are defined as 0.340 and 0.049, respectively, and serum specimens that tested positive have been divided. The positive rate of SMP30 in HCC group was 8.39%, and the positive rates in CH group and healthy control group were 0.55% and 1.21%, respectively. The positive rate of SMP30 in LC group was negative (Figure 2A ). The rate of positivity for anti-SMP30 antibody in patients with HCC was 25.87% and that of the CH group was 4.38%. In the LC group, the rate of positivity for anti-SMP30 antibody was 3.92%; no positive results were detected in the healthy group ( Figure 2B ).
Diagnostic Value of SMP30 and Anti-SMP30 Antibody in Patients With HCC
We measured SMP30 and anti-SMP30 antibodies in serologic specimens from the cohort with HCC and the control cohort and report that the levels of SMP30 and anti-SMP30 antibody are noticeably higher in the HCC group than in other groups. We used ROC curves to analyze the positive test results from the HCC group ( Figure 3) . The AUC of SMP30 is 0.461, indicating that there is a low degree of diagnostic value, with 8.39% sensitivity and 99.15% specificity. Although SMP30 antigen yields poor diagnostic performance in patients with HCC, its corresponding anti-SMP30 antibody has a high diagnostic value, yielding AUC of 0.814, with 25.87% sensitivity and 97.73% specificity ( Table 2 ).
The result of Pearson χ 2 bilateral detection of various indices of case individuals with HCC is shown in Figure 3) . The positive rate in HCC is 69.23% for combined detection of AFP and Anti-SMP30 antibody ( Table 2) . Our results have shown that the combined detection has clinical significance and that it can significantly improve the detection rate of liver cancer (P <.01).
Discussion
Stenner-Liewen et al 7 antigens screened is homologous with human messenger RNA (mRNA) for 165 amino acids near the C-terminal of SMP30. Serologic tests have demonstrated that HCC ranging from 3 through 5 cm has an autoantibody-positive reaction to SMP30. All 20 serum specimens from different kinds of malignant neoplasms and 4 from hepatocirrhosis yielded negative reactions. The results of our serum analyses have suggested that SMP30 is a new HCC-associated antigen and thus can be of great value in the diagnosis of HCC.
In a previous study, 13 the research group had obtained BMP-SMP30 recombinant fusion protein by using genetic-engineering technology. The BMP-SMP30 fusion protein has shown strong water solubility and antigenicity and can be used to detect serum antibody. Our results have shown a 39% positive rate for autoantibody to SMP30 in serum specimens from patients with HCC. However, the molecular weight of BMP-labeled protein is too large for its 45-kD size.
As a result, large-tag protein may be affecting the combining capacity of BMP-SMP30 fusion protein and anti-SMP30 antibody.
HIS-SMP30 recombinant protein, when expressed, is water-insoluble. To resolve this problem, a molecular chaperone coexpression system (BL21[DE3] pLysS-pColdIII-SMP30 -pTf16) has been applied to express HIS-tag SMP30-soluble protein successfully. 14 The label of such a fusion protein is small and does not have a great impact on the exposure of the SMP30 functional epitopes. Despite this finding, anti-SMP30 antibody levels from 143 patients with HCC have been detected by indirect ELISA, with soluble HiS-SMP30 fusion protein as antigen.
Our results have shown that the positive rate is 25.87%, lower than the positive rate of 39% detected in the previous study. There are 3 possible reasons. First, the serum specimens from patients with HCC were tested in different batches, which may have influenced the rate of positivity. Second, the time spent, degree of freshness, and time saved with HCC serum specimens are different, leading to the differences in cutoff values. Third, although the molecular chaperone can promote the soluble expression of SMP30, it is worth considering the effect of molecular chaperone on the antigenic site of SMP30. CH and LC are important risk factors for the occurrence of HCC.
In our study, we further detected the level of serum anti-SMP30 antibody in 137 patients with CH and 51 patients with LC. However, 8 serum specimens tested positive in patients with CH and 2 cases of a positive result in patients with LC. The positivity rate for the presence of anti-SMP30 antibody in the CH and LC groups was significantly lower than that in the HCC group (P <.05). Tumor material itself can induce the immune response of the human body to produce antibody related to the antitumor antigen; however, the specific mechanism is unclear.
Part of the HCC serum anti-SMP30 antibody is negative for 2 possible reasons. First, the results of previous studies have shown that anti-SMP30 antibody appears in the early stages of HCC. The positivity rate for tumors less than 3 cm in diameter was higher than that of patients with tumors of 5 cm in diameter, which suggests that the presence of anti-SMP30 antibody may be an early indicator of HCC.
In our current work, most of our serum specimens were donated by patients with advanced HCC. That type of patient has a lower immune response to tumor antigens, so some of the serum can not detect anti-SMP30 antibody. Second, anti-SMP30 antibody content is low and cannot be detected by ELISA assay. In this work, we detected anti-SMP30 antibody in some AFP-negative serum from patients with HCC. Therefore, anti-SMP30 antibody has great value in the diagnosis of HCC. It suggests that anti-SMP30 antibody production is closely related to the process of liver-cell malignant transformation and further shows that SMP30 autoantibody can be used as a biomarker for aiding with diagnosis of HCC.
We report that the expression of SMP30 decreases in HCCinfected tissues but increases in adjacent cancerous tissues. 8 Further, cell proliferation assay and migration assay results have shown that SMP30 can effectively inhibit the proliferation and migration of HCC cells, suggesting that SMP30 may function as a tumor suppressor. 16, 17 Because of low expression of SMP30 in liver cancer tissues and high expression in adjacent cancer tissues, it is valuable to study whether the appearance of serum anti-SMP30 antibody in patients with HCC is related to the protective reaction for HCC in the early stages.
To study the relationship between serum anti-SMP30 antibody production and SMP30 expression levels, we have developed a method of double-antibody sandwich ELISA to detect SMP30 levels in serum. The results have shown that only 12 cases test positive for SMP30 in 143 cases of HCC, the positive rate is 8.39%, and the positive rate of SMP30 is lower than the antibody levels. Autoantibody to SMP30 has been detected in some HCC serum; however, the corresponding SMP30 has not been detected. Therefore, the mechanism of anti-SMP30 antibody appearance needs to be further investigated. Possible reasons for the low concentration of SMP30 in serum are that SMP30 mainly exists in cells, and normal tissue is rarely secreted into the serum; SMP30 expression in HCC tissues is too low to release in serum; and SMP30 from early stage liver cancer is released into the blood but as a foreign protein, making it easy to be removed by the body.
At present, serum AFP testing is most commonly used for the diagnosis of HCC. However, the sensitivity of AFP is only 25% to 65%, which suggests that approximately 40% of patients with HCC may test false negative. 4 We report that the positive rate of combined detection of anti-SMP30 antibody and AFP has increased to 69.23%, higher than the positive rate of 58.04% yielded by AFP single testing; the difference is statistically significant (P <.01). The combination of 2 biomarkers can improve the sensitivity of the diagnosis of HCC.
In conclusion, we have identified a high level of anti-SMP30 antibody in serum specimens from individuals infected with HCC. The anti-SMP30 antibody in serum has been detected by the indirect ELISA method, and the positive rate is significantly higher than those in patients with CH and those with LC. Anti-SMP30 antibody is expected to be a new serological marker for diagnosis of HCC; it can effectively improve the sensitivity of the diagnosis of HCC, especially in combination with other tumor markers. LM
